TeamDrive
RUS

Partners

Team Drive is engaged in managing two large active projects under cooperation between the Russian investment corporation RUSNANO which is currently implementing the national policy on the development of high-tech sectors and Domain Associates LLC., a leading US-based venture capital firm with an exclusive focus on life sciences. In March 2012 the partners announced the signing of an agreement to be subject to investments in innovative medical technologies.

To perform this task a subsidiary RMI Partners, a company specializing in managing pharmaceutical and medical projects, has been established by Team Drive.


RUSNANO

RUSNANO was founded as a joint stock company in March 2011, through reorganization of state corporation Russian Corporation of Nanotechnologies. RUSNANO is instrumental in realizing government policies for nanoindustry growth, investing in financially effective high-technology projects that guarantee the development of new manufacturing within the Russian Federation. 

Read more..


 Domain Associates LLC

American company Domain Associates LLC was founded in 1985 and is one of the most recognized management companies of venture funds specializing in life sciences projects. Over 260 projects have been created and financed in the course of its existence.

Read more..

Media Center

  • 20 July 2018

    Russian drugs with precise delivery system may become available in five years

    A system of intracellular drug delivery was developed at the Institute of Theoretical and Experimental Biophysics (ITEB) of The Russian Academy of Sciences (RAS). This principle is expected to be used to obtain highly effective anti-inflammatory drugs.

  • 19 July 2018

    China will bring down prices for cancer drugs

    China’s state medical insurance administration will start a new round of negotiations with pharmaceutical companies to add more cancer drugs to the insurance list.

  • 18 July 2018

    Russia and Bulgaria signed cooperation agreement

    Last week, on July 10, 2018, in Sofia Vladislav Shestakov – Director of the State Institute of Drugs and Good Practices, Deputy Head of the State GMP Inspectorate met with Professor Assena Stoimenova, Executive Director of the Bulgarian Drug Agency (Medicines Agency of the Bulgarian Health Ministry).

  • 18 July 2018

    EMA Relocation Countdown: Some Industry Viewpoints

    July 1, 2018 marked the start of the six-month countdown to the European Medicines Agency (EMA) relocation of its operations to Amsterdam. Worryingly, there remains little guidance or clarity from the EMA as to the implications of the move, and Brexit, on the pharma industry.

Read more